Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2011

View Archived Issues

Phase II/III data on antidiabetic efficacy of insulin degludec and insulin degludec/insulin aspart

Gilead Sciences announces CHMP's opinion on Eviplera

Positive CHMP opinion on new indications for Xarelto

European approval recommended for Levemir as add-on to Victoza

Scientists present phase II data on TAS-102 in CRC and potential predictors of efficacy

New data reported from proof-of-principle phase I trial of virosome-based HIV vaccine

Partial hold placed on Immunomedics' trial of yttrium (Y90) clivatuzumab tetraxetan

Faslodex approved in Japan

Indian company prepares new AAV vector-based therapies for cancer

Scientists present 5-year phase II data on odanacatib in postmenopausal women with low BMD

Novel compounds for dermatological disorders presented

Study links gamma-enolase levels to febrile seizures in children

Pegasys approved for new indication in Japan

Asahi Kasei Pharma clear to market osteoporosis therapy in Japan

Synthesis and activity of novel IRAK-4 inhibitors described

Kombiglyze recommended for approval in E.U.

Novel compositions for regulating HER4 reported

U.S. hospital presents new HCV-targeted microRNA products

Additional FDA orphan drug designation for resminostat

Japanese authorities extend indication of Venogloblulin

Piramal Life Sciences patents novel TGF-beta inhibitors for cancer

Ono Pharmaceutical obtains approval in Japan for intravenous Proemend

FDA approves new indication for Soliris

Mucosta approved in Japan for dry eye syndrome

CHMP recommends approval of Alimta for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.